astria therapeutics glp-1 receptor agonist weight management diabetes treatments Understanding agonists and their impact on drug discovery GLP-1-based therapies for diabetes, obesity
Description
, decreased compared to placebo
This framework explains why some patients see dramatic improvements while others see modest changes
Regulatory Status and Absence of Human Safety Data As of 2026, retatrutide has not received approval from the MHRA, FDA, EMA, or any other regulatory authority for human use
GLP-1 RA use was identified as an independent risk factor for food retention (OR 9.19, p = 0.0003)
Nachnani JS, Bulchandani DG, Nookala A, Herndon B, Molteni A, Pandya P, Taylor R, Quinn T, Weide L, Alba LM
[DOI] [PubMed] [Google Scholar] 92
